Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/blood-gas-analyzers-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Point-of-Care Testing · Patent LandscapeBlood Gas Analyzer Patents: Who Holds the Claims and Where the Gaps Sit
- Filings have cooled from their peak. 2021 was the high point at 124 filings; by 2024, the last complete year, that had fallen to 49, a 60% drop across the span.
- No single company dominates. The leader holds 86 families out of 1,466, and the ranked leaders together account for only 32.0% of all records — the rest is a long tail.
- Device claims trail chemistry claims. Only 15.1% of records sit in A61B (diagnosis and surgery) and 5.9% in A61M (body-fluid devices), versus 57.0% in medicinal preparations — hardware claim space is comparatively open.
1,466
Published Records
21%
Top-5 Share of All Records
-60%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (124 records) with 2024 (49) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,466 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Field Overview
What this landscape covers
Blood gas analyzers sit at the intersection of point-of-care diagnostics and analytical chemistry: sensor cartridges, calibration gas handling, temperature correction and clot-risk mitigation are the recurring engineering problems. This landscape covers 1,466 patent families published between 2015 and mid-2026 that combine blood gas measurement terms with these specific device and workflow challenges rather than blood chemistry generally.
The dataset skews heavily toward the chemistry and pharmacology side of the field — medicinal preparations and therapeutic activity classes dominate the IPC composition — while the device-and-diagnosis classes that most readers associate with the analyzer hardware itself carry a smaller, more contestable share of filings.
Filings by year, 2017–2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Blood Gas Analyzers covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Numbers
Filing trend and technology composition
Two views of the same 1,466 records: how filing activity has moved year over year, and how those records distribute across IPC subclasses.
A 2021 peak followed by a real decline
Filings rose from 63 in 2017 to a peak of 124 in 2021, then fell to 49 by 2024 — a 60% drop over that three-year span. 2025 and 2026 figures are not yet comparable, since publication typically lags filing by roughly 18 months.
Chemistry classes dominate; device classes are thinner
A61K (medicinal preparations) and A61P (therapeutic activity) together cover the majority of records, reflecting how many filings frame blood gas measurement as part of a therapeutic or diagnostic-treatment claim. G01N (material analysis) and A61B (diagnosis and surgery) — closer to what most engineers would call the analyzer hardware — are present but far less crowded.
Shares are the percentage of the 1,466 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Blood Gas Analyzers covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Blood Gas Analyzers with Eureka
This page is one run against one query. Ask Eureka your own question about blood gas analyzers and every answer comes back with the patent numbers behind it.
Try EurekaPrior Art Anchors
The most-cited records in this space
Representative Filing
Systems and methods for minimally-invasive arterial blood gas measurement (US20150173662A1)
KONINKLIJKE PHILIPS N.V.
Provided are systems and methods for minimally invasive arterial blood gas measurements. Blood samples are collected using capillary microstructures that minimize patient discomfort and collect samples in a manner such that the samples are not exposed to an environment outside of the sample collection portion. One or more characteristics of the blood sample are then calculated and used to derive one or more arterial blood gas measurements for the sample.Filed by Koninklijke Philips N.V., published 2015-06-25.
Highest-citation patents in scope
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US4786394A | Apparatus for chemical measurement of blood characteristics | 308 |
| 2 | US4929426A | Portable blood chemistry measuring apparatus | 287 |
| 3 | US4188946A | Controllable partial rebreathing anesthesia circuit and respiratory assist device | 262 |
| 4 | US5234835A | Precalibrated fiber optic sensing method | 231 |
| 5 | US20080015487A1 | System and Method for Delivery of Regional Citrate Anticoagulation to Extracorporeal Blood Circuits | 213 |
| 6 | US6873914B2 | Methods and systems for analyzing complex biological systems | 201 |
| 7 | US20100145720A1 | Method of extracting real-time structured data and performing data analysis and decision support in medical r… | 190 |
| 8 | US20120290215A1 | Calculating and Monitoring a Composite Stress Index | 168 |
| 9 | US5459030A | Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoral… | 165 |
| 10 | US4221567A | Sampling and determination of diffusible chemical substances | 159 |
Citation counts favor older filings simply by virtue of longer exposure time; treat them as a signal of influence on later filers, not as current-state importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Blood Gas Analyzers covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Signal Check
What the filing data actually tells you
Three read-throughs from the trend, the concentration figures and the citation table — useful for deciding where diligence effort is worth spending.
Filing Momentum
124 → 49
peak to 2024
The 2021 peak has not held
Filing activity nearly doubled from 2017 to its 2021 peak, then fell 60% by 2024, the last complete year in this dataset. That is a genuine contraction, not a data artifact — but 2025-2026 figures should not be read as confirming or extending it, since they are still filling in.
Based on complete-year data through 2024
Ownership Concentration
21.1% / 32.0%
top 5 / top 10 share of 1,466 records
No single assignee controls the field
The leading assignee holds 86 families, and the top five combined reach just 21.1% of all 1,466 records in scope. Even extending to the top ten adds only another 11 points, to 32.0%. That leaves roughly two-thirds of the field distributed across a long tail of single- and few-filing entrants.
Top 5 and top 10 figures are shares of all records, not of the ranked list
Prior Art Depth
308 citations
on the most-cited record
Foundational patents predate the current filing wave
The most-cited records in this corpus — covering chemical blood measurement apparatus and fiber-optic sensing methods — were filed well before the 2017-2021 filing surge, and still anchor later prosecution. New filings in sensor cartridge design should expect examiners to cite this older core art.
Citation counts favor older filings; treat as influence, not current relevance
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to blood gas analyzers, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Blood Gas Analyzers covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Who's Filing
A fragmented field with no dominant gatekeeper
The assignee ranking spans 100 companies counted by patent family. The leader sits at 86 families; by fifth place that is down to 38, and by tenth place, 28 — a fast taper rather than a plateau.
Leader
86 families
single largest assignee
One clear leader, no runner-up close behind
The top-ranked assignee holds 86 of the 1,466 families in scope, well ahead of fifth place at 38. That gap suggests a genuine first-mover position rather than a statistical artifact of how families were counted.
Family counts, not raw document counts
Mid-Tier
28 families
tenth-ranked assignee
The middle tier is thin
By tenth place, family counts have already dropped to 28 — less than a third of the leader's total. Organizations entering this space now are competing against a shallow, contestable mid-tier rather than an entrenched cluster.
Ranked leaders account for 32.0% of all records combined
Collaboration
10 pairs
co-assignee pairings identified
Co-filing is rare and concentrated
Only ten co-assignee pairs appear across the dataset, and the strongest of them is markedly stronger than the rest. Academic-industry pairings (a university plus a pharmaceutical or hospital partner) account for most of what collaboration exists.
Strongest pair recurs far more often than the others
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| HemaNext Inc | 1 | -50% |
| Corthera Inc | 0 | — |
| Vanderbilt University | 0 | — |
| Biotie Therapies Inc | 0 | -100% |
| Hospira Inc | 0 | — |
| Pericor Therapeutics Inc | 0 | — |
| Siemens Healthcare Diagnostics Inc | 0 | — |
| Henry Ford Health System | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Blood Gas Analyzers covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Next Steps
Where to take this analysis
The figures above describe the field as filed; turning that into a filing or licensing decision means going deeper on specific claims and specific competitors.
Map claim scope on the device classes
A61B and A61M records carry a smaller share of this dataset than the chemistry classes, which is exactly where a narrower claim search is worth running before drafting.
Explore in Patsnap EurekaTrack the leader's recent filings
With the top assignee holding 86 families against a fast-tapering field, watching its most recent publications is a reasonable proxy for where the category is heading next.
Explore in Patsnap EurekaCheck citation-anchored prior art
The highest-cited records in this corpus predate the 2021 filing peak; any new sensor cartridge or calibration claim should be checked against them directly.
Explore in Patsnap EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Blood Gas Analyzers covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Common Questions
Frequently asked questions
The dataset's leading assignee holds 86 patent families out of 1,466 in scope, which is a meaningful lead over fifth place at 38 families. Even so, the top five assignees combined account for only 21.1% of all records, and the top ten reach 32.0%. That means no company controls the field outright; ownership is concentrated at the very top but thins out quickly after that.
Filing activity rose from 63 in 2017 to a peak of 124 in 2021, then fell to 49 by 2024, a 60% decline over that three-year span. 2024 is the most recent year with complete data; figures for 2025 and 2026 are still filling in because publication typically lags filing by about 18 months, so it is too early to call the current trajectory. Based on complete years, the field has contracted from its 2021 high.
By IPC subclass, medicinal preparations (A61K) and therapeutic activity (A61P) account for the largest shares of the 1,466 records, at 57.0% and 32.7% respectively. Material analysis and testing (G01N) and diagnosis and surgery (A61B) — the classes closest to sensor and device engineering — cover 19.2% and 15.1%. This split reflects a dataset weighted toward chemistry and therapeutic framing rather than pure hardware claims.
Device-and-workflow classes carry a noticeably smaller share of filings than the chemistry classes: A61M, covering devices for body fluids, sits at only 5.9% of records. Sub-areas like sensor cartridge clot-risk mitigation, in-line calibration gas delivery, and maintenance-downtime self-diagnostics show up in fewer filings relative to the broader chemistry space, suggesting narrower prior art density there. That does not guarantee an open path, but it does mean fewer blocking claims to search around.
The assignee ranking covers 100 companies counted by family, and ownership tapers quickly: the leader holds 86 families, fifth place holds 38, and tenth place holds 28. The top five combined reach 21.1% of all 1,466 records, and the top ten reach 32.0%, leaving roughly two-thirds of filings spread across a long tail of smaller and single-filing entrants. This is a fragmented field rather than one dominated by a handful of gatekeepers.
Answers are grounded in the same dataset. Derived from a Patsnap search on Blood Gas Analyzers covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Blood Gas Analyzers in depth with Eureka
Go past this page: query the whole blood gas analyzers corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.